Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMEBOFW)

• Drug Name: Clofazimine Drug Info
• Synonyms: clofazimine; 2030-63-9; Lamprene; Lampren; Chlofazimine; Clofazimina; Clofaziminum; Clofaziminum [INN-Latin]; B 663 (Pharmaceutical); Clofazimina [INN-Spanish]; B-663; NSC-141046; G 30320; UNII-D959AE5USF; B 663 (VAN); C27H22Cl2N4; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin; B 663; 3-(p-Chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine; EINECS 217-980-2; CFZ; SMP2_000339; B 663, pharmaceutical; G-30320; Lamprene (TN); Liposome-encapsulated clofazimine; Clofazimine [USAN:INN:BAN]; G-30,320; Clofazimine (JAN/USP/INN); N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(isopropylimino)phenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(1-methylethyl)imino)-2-phenazinamine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-2-phenazinamine; N,5-bis(4-chlorophenyl)-3-(propan-2-ylimino)-3,5-dihydrophenazin-2-amine; (3Z)-N,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-3,5-dihydrophenazin-2-amine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin [German]; Riminophenazine
• Therapeutic Class: Antiinflammatory Agents
• Cross-matching ID:
  PubChem CID: 2794
  ChEBI ID: CHEMBL3749
  CAS Number: CAS 2030-63-9
  TTD Drug ID: D0S5UH
  VARIDT Drug ID: DR00669
  INTEDE Drug ID: DR0346
  ACDINA Drug ID: D00956

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Cysteine and methionine metabolism	2.01	0.00e+0	43/50 (86%)	PSAT1;PHGDH;ADI1;...
Ferroptosis	2.01	0.00e+0	36/41 (87.8%)	SLC7A11;SLC39A8;FTH1;...
One carbon pool by folate	1.81	4.80e-2	15/20 (75%)	SHMT2;MTHFD1;ALDH1L1;...
Amino sugar and nucleotide sugar metabolism	1.80	3.84e-2	38/48 (79.17%)	GNE;HK2;UGDH;...
Glycolysis / Gluconeogenesis	1.78	3.84e-2	56/67 (83.58%)	ADH5;PCK2;ADH1B;...
Tyrosine metabolism	1.74	4.64e-2	30/36 (83.33%)	ADH5;COMT;ADH1B;...
Viral myocarditis	-1.70	4.28e-2	53/60 (88.33%)	EIF4G1;CASP3;ABL1;...
Regulation of actin cytoskeleton	-1.70	4.19e-2	185/218 (84.86%)	ITGA8;MYL9;HRAS;...
Platelet activation	-1.72	4.19e-2	106/124 (85.48%)	PRKACA;PIK3R5;MAPK11;...
Amoebiasis	-1.72	4.65e-2	99/102 (97.06%)	RAB5C;COL1A1;COL4A2;...
Hedgehog signaling pathway	-1.73	4.32e-2	43/56 (76.79%)	SCUBE2;PRKACG;CDON;...
Focal adhesion	-1.76	3.89e-2	180/201 (89.55%)	PIK3R3;BIRC3;CCND3;...
Staphylococcus aureus infection	-1.76	4.54e-2	72/95 (75.79%)	KRT31;HLA-DOB;SELP;...
Graft-versus-host disease	-1.81	4.54e-2	32/42 (76.19%)	HLA-DPA1;FASLG;FAS;...
Leishmaniasis	-1.91	4.19e-2	67/77 (87.01%)	MAPK11;RELA;MAPK14;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H	Hide ▲
MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H	Hide ▲

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.04uM - 10uM	24H	Show ▼

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.04uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Umbilical vein

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HUVEC-C	CVCL_2959	Homo sapiens	0.04uM - 10uM	24H	Show ▼